Floatz logo

Methylphenidate

Post-Traumatic Stress Disorder

VA Office of Research and DevelopmentSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Post-Traumatic Stress Disorder cohort.

Asset / SponsorPhaseRating
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Queen's University
Phase 4BBB
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Escitalopram
New York State Psychiatric Institute
Phase 4BB
Midomafetamine
MAPS Europe B.V.
Phase 2B

View all 39 →

Same molecule, other indications

Methylphenidate is also rated in:

attention deficit-hyperactivity disorderActive
BBB
Indicative · Phase 4
76 / 100
View asset →
multiple sclerosisDormant
BB
Indicative · Phase 3
70 / 100
View asset →
Alzheimer diseaseActive
BB
Indicative · Phase 4
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →